文献速递临床生化质量管理与危急值

试剂批间差异检测的样本量与拒绝限:CLSI EP26-A 方案在真实临床生化数据中的适用性分析

Sample size and rejection limits for detecting reagent lot variability: analysis of the applicability of the Clinical and Laboratory Standards Institute (CLSI) EP26-A protocol to real-world clinical chemistry data.
PubMed 文献 · Clin Chem Lab Med · 2020-07-06

该研究将 CLSI EP26-A 方案应用于三个临床实验室的 83 项生化检测,采用三种临界差异定义确定可检出试剂批间差异的样本量与拒绝限。结果显示过半项目每个决策水平仅需 1 例患者样本,多数情况下拒绝限为 0.6 倍临界差异,但样本量与拒绝限随临界差异定义方式变化,部分情况不可行或 EP26-A 未提供所需信息。

要点

  • 过半生化项目每个决策水平仅需 1 例患者样本即可评估试剂批间差异
  • 多数情况下可≥90% 概率检出批间差异的拒绝限为 0.6 倍临界差异
  • 样本量与拒绝限随临界差异定义方式不同而变化,部分情况不可行

核心结论

  • CLSI EP26-A 未提供全部必要答案,当其无指导时需替代性实用方法。

研究设计与样本

  • 将 CLSI EP26-A 方案应用于三个临床实验室的 83 项生化检测,并以三种方式定义各检测的临界差异。

主要发现

  • 过半生化项目每个决策水平仅需 1 例患者样本即可评估试剂批间差异。
  • 多数情况下可≥90% 概率检出试剂批间差异的拒绝限为 0.6 倍临界差异。
  • 样本量与拒绝限随临界差异定义方式而变化,部分情况得到不可行的样本量或拒绝限。
  • 部分情况在 EP26-A 中未找到满足预期统计功效的样本量与拒绝限信息。

关键数值与推荐

  • 临界差异采用三种标准定义:基于生物学变异的参考变化值与总允许误差,以及外部质量保证机构的可接受限。

临床怎么用

  • 新试剂批号使用前可参照 EP26-A 确定样本量与拒绝限,但需注意其随临界差异定义方式变化。
  • 当 EP26-A 未提供满足统计功效的指导时,应采用替代性实用方法评估试剂批间差异。

局限性

  • EP26-A 未涵盖全部情形,部分情况无法获得满足预期统计功效的样本量与拒绝限信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To maintain the consistency of laboratory test results, between-reagent lot variation should be verified before using new reagent lots in clinical laboratory. Although the Clinical and Laboratory Standards Institute (CLSI) document EP26-A deals with this issue, evaluation of reagent lot-to-lot difference is challenging in reality. We aim to investigate a practical way for determining between-reagent lot variation using real-world data in clinical chemistry. METHODS: The CLSI EP26-A protocol was applied to 83 chemistry tests in three clinical labs. Three criteria were used to define the critical difference (CD) of each test as follows: reference change value and total allowable error, which are based on biological variation, and acceptable limits by external quality assurance agencies. The sample size and rejection limits that could detect CD between-reagent lots were determined. RESULTS: For more than half of chemistry tests, reagent lot-to-lot differences could be evaluated using only one patient sample per decision level. In many cases, the rejection limit that could detect reagent lot-to-lot difference with ≥90% probability was 0.6 times CD. However, the sample size and rejection limits vary depending on how the CD is defined. In some cases, impractical sample size or rejection limits were obtained. In some cases, information on sample size and rejection limit that met intended statistical power was not found in EP26-A. CONCLUSIONS: The CLSI EP26-A did not provide all necessary answers. Alternative practical approaches are suggested when CLSI EP26-A does not provide guidance.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Kim S, Chang J, Kim SK, et al. Sample size and rejection limits for detecting reagent lot variability: analysis of the applicability of the Clinical and Laboratory Standards Institute (CLSI) EP26-A protocol to real-world clinical chemistry data. Clin Chem Lab Med. 2020. PMID: 32628625. doi:10.1515/cclm-2020-0454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。